>

Hans Wijers - GlaxoSmithKline PLC Independent Non-Executive Director

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:6em;padding-top: 0px;;'>G</div>
GSK -- USA Stock  

Earning Report: May 6, 2020  

  Director
Mr. Hans Wijers is no longer Independent NonExecutive Director at GlaxoSmithKline Plc effective 5 May 2016. He has a broad range of business economic and political experience having served as Chief Executive Officer and Chairman at Akzo Nobel NV from 2002 to 2012. Hans had a long and distinguished career in academia public service and strategy consulting. He served as a senior vice president of the Boston Consulting Group from 1998 to 2002. Hans is Chairman of the Supervisory Board of Heineken NV and also Deputy Chairman and NonExecutive Director of Royal Dutch Shell. He is also Chairman of the Supervisory Board of AFC Ajax.
Age: 64  Director Since 2013      
(44) 20 8047 7807  www.gsk.com

Management Efficiency

The company has 36.63 B in debt with debt to equity (D/E) ratio of 182.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. GlaxoSmithKline PLC has Current Ratio of 0.8 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Jennifer DoudnaJohnson Johnson
2018
Vicki SatoBristol Myers Squibb Company
2017
Marschall RungeEli Lilly And Company
2013
Baroness VaderaAstrazeneca PLC
2011
Robert HuginAllergan Plc
2019
Patrick OSullivanAllergan Plc
2013
Pamela CraigMerck Company
2015
Eugene WashingtonJohnson Johnson
2012
Togo WestBristol Myers Squibb Company
2015
Rochelle LazarusMerck Company
2004
Susan LindquistJohnson Johnson
2004
Thomas CechMerck Company
2009
Thomas GlocerMerck Company
2007
Michel DemareAstrazeneca PLC
2019
Ronald WilliamsJohnson Johnson
2011
Marcus WallenbergAstrazeneca PLC
1999
Craig ThompsonMerck Company
2008
James SmithPfizer
2014
Dennis AusielloPfizer
2015
Michael GreenbergAllergan Plc
2018
Mark WeinbergerJohnson Johnson
2019

Company Summary

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 99437 people.GlaxoSmithKline PLC (GSK) is traded on BATS Exchange in USA. It is located in 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom and employs 99,437 people. GlaxoSmithKline PLC is listed under Pharmaceutical Products category by Fama And French industry classification.

GlaxoSmithKline PLC Leadership Team

Vindi Banga, Senior Independent Non-Executive DirectorView
Lynn Elsenhans, Independent Non-Executive DirectorView
Luke Miels, President - Global PharmaceuticalsView
Hal Barron, Chief Scientific Officer, President - Research & Development, Executive DirectorView
Daniel Podolsky, Non-Executive Independent DirectorView
Emma Walmsley, Chief Executive Officer, Executive DirectorView
Luc Debruyne, President - Global VaccinesView
Andrew Witty, CEO, Executive DirectorView
Brian McNamara, Chief Executive Officer - GSK Consumer HealthcareView
Roy Anderson, Non-Executive Independent DirectorView
Philip Hampton, Independent Non-Executive DirectorView
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. CommitteeView
Vivienne Cox, Non-Executive Independent DirectorView
Bill Louv, Senior Vice President - Core Business ServicesView
Diana Conrad, Senior Vice President - Human ResourcesView
Roger Connor, President - Global Manufacturing & SupplyView
Abbas Hussain, President Global PharmaceuticalsView
Phil Thomson, Senior Vice President - Global CommunicationsView
Judy Lewent, Non-Executive Independent DirectorView
Hans Wijers, Independent Non-Executive DirectorView
Stephanie Burns, Non-Executive Independent DirectorView
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. CommitteeView
Urs Rohner, Non-Executive Independent DirectorView
Marvinder Banga, Senior Non-Executive Independent DirectorView
Deryck Maughan, Senior Independent Non-Executive DirectorView
Jesse Goodman, Non-Executive Independent DirectorView
Laurie Glimcher, Non-Executive Independent DirectorView
Nick Hirons, Senior Vice President - Global Ethics and ComplianceView
Sally Jackson, Senior Vice President - Global Communications and CEO OfficeView
James Ford, Senior Vice President General CounselView
Victoria Whyte, Company SecretaryView
Daniel Troy, Sr. VP and General CounselView
Shah Hussain, President - Europe, Japan & EMAPView
Manvinder Banga, Non-Executive DirectorView
David Redfern, Chief Strategy OfficerView
Patrick Vallance, President - Pharmaceuticals R&DView
Stacey Cartwright, Non-Executive Independent DirectorView
Regis Simard, President - Pharmaceutical Supply ChainView
Jonathan Symonds, Independent Non-Executive Chairman of the BoardView
Iain Mackay, Chief Financial Officer, Executive DirectorView
Karenann Terrell, Chief Digital & Technology OfficerView
Deborah Waterhouse, Chief Executive Officer - ViiV HealthcareView
Claire Thomas, Senior Vice President - Human ResourcesView

Stock Performance Indicators

Did you try this?

Run Portfolio Optimization Now

   

Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page